The incident user design in comparative effectiveness research - PubMed (original) (raw)
Review
doi: 10.1002/pds.3334. Epub 2012 Oct 1.
Barbara A Bartman, Becky A Briesacher, Neil S Fleming, Tobias Gerhard, Cynthia J Kornegay, Parivash Nourjah, Brian Sauer, Glen T Schumock, Art Sedrakyan, Til Stürmer, Suzanne L West, Sebastian Schneeweiss
Affiliations
- PMID: 23023988
- DOI: 10.1002/pds.3334
Review
The incident user design in comparative effectiveness research
Eric S Johnson et al. Pharmacoepidemiol Drug Saf. 2013 Jan.
Abstract
Comparative effectiveness research includes cohort studies and registries of interventions. When investigators design such studies, how important is it to follow patients from the day they initiated treatment with the study interventions? Our article considers this question and related issues to start a dialogue on the value of the incident user design in comparative effectiveness research. By incident user design, we mean a study that sets the cohort's inception date according to patients' new use of an intervention. In contrast, most epidemiologic studies enroll patients who were currently or recently using an intervention when follow-up began. We take the incident user design as a reasonable default strategy because it reduces biases that can impact non-randomized studies, especially when investigators use healthcare databases. We review case studies where investigators have explored the consequences of designing a cohort study by restricting to incident users, but most of the discussion has been informed by expert opinion, not by systematic evidence.
Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Similar articles
- Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.
Suissa S, Moodie EE, Dell'Aniello S. Suissa S, et al. Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):459-468. doi: 10.1002/pds.4107. Epub 2016 Sep 9. Pharmacoepidemiol Drug Saf. 2017. PMID: 27610604 - Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.
Roberts AW, Dusetzina SB, Farley JF. Roberts AW, et al. J Comp Eff Res. 2015 Jan;4(1):27-35. doi: 10.2217/cer.14.53. J Comp Eff Res. 2015. PMID: 25565067 Free PMC article. - Probabilistic bias analysis in pharmacoepidemiology and comparative effectiveness research: a systematic review.
Hunnicutt JN, Ulbricht CM, Chrysanthopoulou SA, Lapane KL. Hunnicutt JN, et al. Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1343-1353. doi: 10.1002/pds.4076. Epub 2016 Sep 5. Pharmacoepidemiol Drug Saf. 2016. PMID: 27593968 Free PMC article. Review. - New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
Luijken K, Spekreijse JJ, van Smeden M, Gardarsdottir H, Groenwold RHH. Luijken K, et al. Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):960-974. doi: 10.1002/pds.5258. Epub 2021 May 10. Pharmacoepidemiol Drug Saf. 2021. PMID: 33899305 Free PMC article. Review. - Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.
Acton EK, Willis AW, Hennessy S. Acton EK, et al. Pharmacoepidemiol Drug Saf. 2023 Jan;32(1):9-18. doi: 10.1002/pds.5547. Epub 2022 Oct 20. Pharmacoepidemiol Drug Saf. 2023. PMID: 36216785 Free PMC article.
Cited by
- Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib.
Sultan I, Waterhouse DM, Chopra D, Lonshteyn A, Weycker D, Delea TE, Stollenwerk B. Sultan I, et al. Adv Ther. 2024 Dec;41(12):4648-4659. doi: 10.1007/s12325-024-03020-7. Epub 2024 Oct 29. Adv Ther. 2024. PMID: 39470877 Free PMC article. - Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration.
Patel S, Walsh J, Pinnell D, Pei S, Chen W, Rojas J, Rathod A, Johnson J, Gawron A, Curtis JR, Baker JF, Cannon GW, Wu D, Lai M, Sauer BC. Patel S, et al. Medicine (Baltimore). 2024 Sep 13;103(37):e39476. doi: 10.1097/MD.0000000000039476. Medicine (Baltimore). 2024. PMID: 39287304 Free PMC article. - Pancreatic cancer risk in diabetic patients using the Japanese Regional Insurance Claims.
Satoh T, Nakatani E, Ariyasu H, Kawaguchi S, Ohno K, Itoh H, Hayashi K, Usui T. Satoh T, et al. Sci Rep. 2024 Jul 23;14(1):16958. doi: 10.1038/s41598-024-67505-9. Sci Rep. 2024. PMID: 39043788 Free PMC article. - Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.
Narasaki Y, Kovesdy CP, You AS, Sumida K, Mallisetty Y, Surbhi S, Thomas F, Amin AN, Streja E, Kalantar-Zadeh K, Rhee CM. Narasaki Y, et al. Lancet Reg Health Am. 2024 Jun 18;36:100814. doi: 10.1016/j.lana.2024.100814. eCollection 2024 Aug. Lancet Reg Health Am. 2024. PMID: 38993538 Free PMC article. - High-Throughput Computing to Automate Population-Based Studies to Detect the 30-Day Risk of Adverse Outcomes After New Outpatient Medication Use in Older Adults with Chronic Kidney Disease: A Clinical Research Protocol.
Abdullah SS, Rostamzadeh N, Muanda FT, McArthur E, Weir MA, Sontrop JM, Kim RB, Kamran S, Garg AX. Abdullah SS, et al. Can J Kidney Health Dis. 2024 Jan 6;11:20543581231221891. doi: 10.1177/20543581231221891. eCollection 2024. Can J Kidney Health Dis. 2024. PMID: 38186562 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources